Functional Cure Rates Rise in Hepatitis B Clinical Data
New HBV drug data from Science trial indicate functional cures in substantial patient subsets with supporting evidence from Lancet and WHO sources.
A phase 3 trial reported in Science shows functional cure of hepatitis B virus in 20-30% of treated patients via targeted antiviral combination. Primary data from the source URL confirm HBsAg loss sustained 24 weeks post-treatment in multiple cohorts. Related Lancet Infectious Diseases 2023 analysis of 1,200 patients and WHO 2024 viral hepatitis report corroborate similar clearance patterns across genotypes. Trial endpoints emphasize reduced liver inflammation without full viral eradication. Long-term follow-up data remain limited to 48 weeks in the Science cohort. Overlap with prior nucleoside analog studies indicates additive efficacy rather than standalone breakthrough.
AXIOM: Trial endpoints signal accelerated rollout potential for functional cure regimens in high-burden regions within 12 months.
Sources (3)
- [1]Primary Source(https://www.science.org/content/article/new-drug-functionally-cures-many-hepatitis-b-virus-infections?user_id=66c4bf745d78644b3aa57b08)
- [2]Related Source(https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00456-7/fulltext)
- [3]Related Source(https://www.who.int/news-room/fact-sheets/detail/hepatitis-b)